Macrophage‐specific FGF12 promotes liver fibrosis progression in mice. Issue 3 (17th March 2023)

• Record Type: Journal Article
• Authors: Li, Santie; Zhou, Bin; Xue, Mei; Zhu, Junjie; Tong, Gaozan; Fan, Junfu; Zhu, Kunxuan; Hu, Zijing; Chen, Rui; Dong, Yonggan; Chen, Yiming; Lee, Kwang Youl; Li, Xiaokun; Jin, Litai; Cong, Weitao
• Is Part Of: Hepatology. Volume 77:Issue 3(2023)
• Page Start: 816
• Page End: 833
• Publication Date: 2023-03-17
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.32640
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Chronic liver diseases are associated with the development of liver fibrosis. Without treatment, liver fibrosis commonly leads to cirrhosis and HCC. FGF12 is an intracrine factor belonging to the FGF superfamily, but its role in liver homeostasis is largely unknown. This study aimed to investigate the role of FGF12 in the regulation of liver fibrosis. Approach and Results: FGF12 was up‐regulated in bile duct ligation (BDL)–induced and CCL4 ‐induced liver fibrosis mouse models. Expression of FGF12 was specifically up‐regulated in nonparenchymal liver cells, especially in hepatic macrophages. By constructing myeloid‐specific FGF12 knockout mice, we found that deletion of FGF12 in macrophages protected against BDL‐induced and CCL4 ‐induced liver fibrosis. Further results revealed that FGF12 deletion dramatically decreased the population of lymphocyte antigen 6 complex locus C high macrophages in mouse fibrotic liver tissue and reduced the expression of proinflammatory cytokines and chemokines. Meanwhile, loss‐of‐function and gain‐of‐function approaches revealed that FGF12 promoted the proinflammatory activation of macrophages, thus inducing HSC activation mainly through the monocyte chemoattractant protein‐1/chemokine (C–C motif) receptor 2 axis. Further experiments indicated that the regulation of macrophage activation by FGF12 was mainly mediated through the Janus kinase–signal transducer of activators of transcription pathway. Finally, the results revealed that FGF12 expression correlates with the severity of fibrosis across the spectrum of fibrogenesis in human liver samples. Conclusions: FGF12 promotes liver fibrosis progression. Therapeutic approaches to inhibit macrophage FGF12 may be used to combat liver fibrosis in the future. Abstract :